Obexelimab + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Sep 17, 2024 → Sep 1, 2026
NCT ID
NCT06559163About Obexelimab + Placebo
Obexelimab + Placebo is a phase 2 stage product being developed by Zenas BioPharma for Systemic Lupus Erythematosus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06559163. Target conditions include Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06559163 | Phase 2 | Recruiting |
| NCT06564311 | Phase 2 | Active |
Competing Products
20 competing products in Systemic Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| E6742 | Eisai | Phase 1/2 | 41 |
| KHK4827 | Kyowa Kirin | Phase 1 | 33 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |